Similarly, vandetanib, a small molecule inhibitor of VEGFR and EGFR signalling, did not demonstrate significant clinical benefit in recurrent ovarian cancer (Annunziata et al, 2010). The gene discussed is EGFR; the disease is ovarian carcinoma.